* Terns Pharmaceuticals Inc reported a quarterly adjusted loss of 28 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -42 cents. The mean expectation of ten analysts for the quarter was for a loss of 32 cents per share. Wall Street expected results to range from -37 cents to -30 cents per share.
* Reported revenue was zero; analysts expected zero.
* Terns Pharmaceuticals Inc's reported EPS for the quarter was a loss of 28 cents.
* The company reported a quarterly loss of $21.95 million.
* Terns Pharmaceuticals Inc shares had fallen by 10.6% this quarter and gained 14.9% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 6.1% in the last three months.
* In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Terns Pharmaceuticals Inc is 18.00 This summary was machine generated from LSEG data November 12 at 11:15 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.32 -0.28 Beat
Jun. 30 2024 -0.34 -0.31 Beat
Mar. 31 2024 -0.34 -0.30 Beat
Dec. 31 2023 -0.29 -0.29 Met
Comments